Enveric Biosciences Reports Mechanistic Data for Lead Candidate EB-003

Enveric Biosciences has reported new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin-mediated signaling downstream of the 5-HT₂ A receptor. The data were generated using proprietary bioluminescence resonance energy transfer (BRET) assays, which indicate that EB-003 exhibits a modest preference toward β-arrestin over Gq signaling relative to serotonin, the native ligand of the receptor. The findings suggest that therapeutic benefit can arise from activation of either pathway, supporting Enveric's strategy of designing non-hallucinogenic neuroplastogens for streamlined treatment paradigms.